56 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Novel, highly potent systemic glucokinase activators for the treatment of Type 2 Diabetes Mellitus.
Merck
Discovery of a Novel 2,6-Disubstituted Glucosamine Series of Potent and Selective Hexokinase 2 Inhibitors.
Glaxosmithkline
Structure-Activity Relationship of Azaindole-Based Glucokinase Activators.
Servier Research Institute Of Medicinal Chemistry
Design and Synthesis of Acetylenyl Benzamide Derivatives as Novel Glucokinase Activators for the Treatment of T2DM.
Yuhan Research Institute
Small molecule disruptors of the glucokinase-glucokinase regulatory protein interaction: 4. Exploration of a novel binding pocket.
Amgen
C5-Alkyl-2-methylurea-Substituted Pyridines as a New Class of Glucokinase Activators.
Amgen
Discovery of 3-(4-methanesulfonylphenoxy)-N-[1-(2-methoxy-ethoxymethyl)-1H-pyrazol-3-yl]-5-(3-methylpyridin-2-yl)-benzamide as a novel glucokinase activator (GKA) for the treatment of type 2 diabetes mellitus.
Yuhan Research Institute
Discovery of novel urea derivatives as dual-target hypoglycemic agents that activate glucokinase and PPAR¿.
Chinese Academy Of Medical Sciences & Peking Union Medical College
Small molecule disruptors of the glucokinase-glucokinase regulatory protein interaction: 1. Discovery of a novel tool compound for in vivo proof-of-concept.
Amgen
Small molecule disruptors of the glucokinase-glucokinase regulatory protein interaction: 2. Leveraging structure-based drug design to identify analogues with improved pharmacokinetic profiles.
Amgen
Discovery of an intravenous hepatoselective glucokinase activator for the treatment of inpatient hyperglycemia.
Pfizer
Identification of a new class of glucokinase activators through structure-based design.
Array Biopharma
Pyrimidone-based series of glucokinase activators with alternative donor-acceptor motif.
Pfizer
Small-Molecule Allosteric Activation of Human Glucokinase in the Absence of Glucose.
Florida State University
Discovery of a novel phenylethyl benzamide glucokinase activator for the treatment of type 2 diabetes mellitus.
Yuhan Research Institute
The discovery of a novel series of glucokinase activators based on a pyrazolopyrimidine scaffold.
Astrazeneca
The design and synthesis of indazole and pyrazolopyridine based glucokinase activators for the treatment of type 2 diabetes mellitus.
Pfizer
Discovery of (S)-6-(3-cyclopentyl-2-(4-(trifluoromethyl)-1H-imidazol-1-yl)propanamido)nicotinic acid as a hepatoselective glucokinase activator clinical candidate for treating type 2 diabetes mellitus.
Pfizer
Design, synthesis, and pharmacological evaluation of benzamide derivatives as glucokinase activators.
Chinese Academy Of Sciences
Pyridones as glucokinase activators: identification of a unique metabolic liability of the 4-sulfonyl-2-pyridone heterocycle.
Pfizer
Design of a potent, soluble glucokinase activator with increased pharmacokinetic half-life.
Astrazeneca R&D
Design, synthesis, and pharmacological evaluation of N-(4-mono and 4,5-disubstituted thiazol-2-yl)-2-aryl-3-(tetrahydro-2H-pyran-4-yl)propanamides as glucokinase activators.
Chinese Academy Of Sciences
The design and optimization of a series of 2-(pyridin-2-yl)-1H-benzimidazole compounds as allosteric glucokinase activators.
Banyu Tsukuba Research Institute
Discovery and structure-activity relationships of a novel class of quinazoline glucokinase activators.
Banyu Tsukuba Research Institute
Discovery of novel 2-(pyridine-2-yl)-1H-benzimidazole derivatives as potent glucokinase activators.
Banyu Tsukuba Research Institute
Structure-activity relationships of 3,5-disubstituted benzamides as glucokinase activators with potent in vivo efficacy.
Banyu Tsukuba Research Institute
Discovery of novel 3,6-disubstituted 2-pyridinecarboxamide derivatives as GK activators.
Banyu Tsukuba Research Institute
Discovery of potent and orally active 3-alkoxy-5-phenoxy-N-thiazolyl benzamides as novel allosteric glucokinase activators.
Banyu Tsukuba Research Institute
Identification of novel and potent 2-amino benzamide derivatives as allosteric glucokinase activators.
Banyu Tsukuba Research Institute
SAR, pharmacokinetics, safety, and efficacy of glucokinase activating 2-(4-sulfonylphenyl)-N-thiazol-2-ylacetamides: discovery of PSN-GK1.
(Osi) Prosidion
Design of a potent, soluble glucokinase activator with excellent in vivo efficacy.
Astrazeneca R&D
Discovery, synthesis and biological evaluation of novel glucokinase activators.
Astrazeneca
Discovery of a Partial Glucokinase Activator Clinical Candidate: Diethyl ((3-(3-((5-(Azetidine-1-carbonyl)pyrazin-2-yl)oxy)-5-isopropoxybenzamido)-1
Bristol Myers Squibb
Novel quinazoline derivatives bearing various 6-benzamide moieties as highly selective and potent EGFR inhibitors.
Beijing Normal University
Investigating small molecules to inhibit germinal center kinase-like kinase (GLK/MAP4K3) upstream of PKC? phosphorylation: Potential therapy to modulate T cell dependent immunity.
Biogen
Design, synthesis, and pharmacological evaluation of 2-(4-sulfonylphenyl)-2-[(E)-pyrrolidin-1-ylimino]-N-thiazoleacetamides as glucokinase activators.
Chiba University
Discovery and preclinical development of AR453588 as an anti-diabetic glucokinase activator.
Array Biopharma
Molecular Dynamics Simulations and Kinetic Measurements to Estimate and Predict Protein-Ligand Residence Times.
Istituto Italiano Di Tecnologia
Novel Series of Potent Glucokinase Activators Leading to the Discovery of AM-2394.
Amgen
5-Alkyl-2-urea-Substituted Pyridines: Identification of Efficacious Glucokinase Activators with Improved Properties.
Amgen
Synthesis and biological evaluation of 3-aryl-4-indolyl-maleimides as potent mutant isocitrate dehydrogenase-1 inhibitors.
Zhejiang University
ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells.
University Of Florida
Discovery and Structure-Guided Optimization of Diarylmethanesulfonamide Disrupters of Glucokinase-Glucokinase Regulatory Protein (GK-GKRP) Binding: Strategic Use of a N ? S (nN ? ?*S-X) Interaction for Conformational Constraint.
Amgen
Discovery of cycloalkyl-fused N-thiazol-2-yl-benzamides as tissue non-specific glucokinase activators: Design, synthesis, and biological evaluation.
China Pharmaceutical University
Discovery of potent and orally active 1,4-disubstituted indazoles as novel allosteric glucokinase activators.
Takeda California
Discovery of orally active hepatoselective glucokinase activators for treatment of Type II Diabetes Mellitus.
Merck
De novo design of protein kinase inhibitors by in silico identification of hinge region-binding fragments.
University Of Dundee